基本信息
views: 61
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
My entire career is focused on molecular pharmacology of adult neurodegenerative diseases, with special emphasis on mitochondrial involvement in neurodegeneration. I am a clinician-scientist and have provided clinical care and clinical research in all degenerative adult diseases, with my major focus being Parkinson's disease. I have held several IND's for drug testing and invented the use of R(+) pramipexole (PPX) in brain diseases. I hold an active Physician-Sponsor IND for R(+)PPX. I was Director of the University of Virginia Morris Udall Parkinson's Research Center of Excellence (NIH funded 2000-2010, Director 2008-2010). I was Chair of Neurology at Virginia Commonwealth University 2009-2013 and founding Director of the VCU Parkinson's and Movement Disorders Center 2009-2015. I have retired from academic medicine and started a NFP company (Neurodegeneration Therapeutics, Inc) to pursue laboratory research using induced pluripotential stem cells (iPSC's) from persons with degenerative diseases. Our focus is on "personalized pharmacology" to emphasize treatments for specific individuals as opposed to large groups, which is the traditional paradigm for drug development.
Research Interests
Papers共 124 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
The American Journal of Human Geneticsno. 1 (2021): 8-15
American journal of human geneticsno. 9 (2021): 1809-1810
Journal of Stem Cell Research and Medicineno. 1 (2018)
Journal of Systems and Integrative Neuroscienceno. 6 (2017)
Load More
Author Statistics
#Papers: 116
#Citation: 6905
H-Index: 46
G-Index: 82
Sociability: 6
Diversity: 0
Activity: 0
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn